News

Former Editor, The Wall Street Journal
James Willhite was an editor with The Wall Street Journal's money & investing team based in London.
The Munich Eye2h
Novavax's COVID-19 Vaccine Advances Towards Full FDA Approval
Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.
Reporter, Ottawa Bureau, The Wall Street Journal
Paul Vieira covers Canada for The Wall Street Journal, and is based in Ottawa.
FDA may ask Novavax to conduct additional trials of its Covid-19 vaccine to receive full approval
The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...
Novavax told by FDA to conduct additional study for COVID vaccine - report
The U.S. FDA is asking Novavax (NASDAQ:NVAX) to conduct an additional randomized, controlled study of its COVID-19 vaccine ...
US FDA asks Novavax to complete new clinical trial for delayed COVID-19 shot, WSJ reports
Federal regulators have asked Novavax to complete an additional clinical trial on its COVID-19 vaccine after previously ...
Wyoming Tribune Eagle14h
HHS Announces Plans to Pay Moderna $176 Million for mRNA Flu Vaccine
On Tuesday, the U.S. Department of Health and Human Services announced that the government will invest $176 million in ...
The Mountaineer19h
Novavax COVID Vaccine Moves Closer to Full FDA Approval
Novavax is working closely with federal drug regulators to get full approval for its COVID shot. The vaccine is the only ...
Joe Scott on MSN22h
How The COVID-19 Vaccine Could Lead To A Cure For Cancer ¦ Answers With Joe
The mRNA technology behind the Pfizer and Moderna vaccines are groundbreaking, but their potential goes way beyond COVID-19.